Teva's $4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the needle on its planned replacement, enduring another rejection from European reviewers.
European regulators recommended against Teva Pharmaceutical's laquinimod, marring the Isreali company's odds of crossing the finish line with its once-promising multiple sclerosis treatment, a drug it hopes can dull the blow of the soon-to-go-generic Copaxone.
Regulators in Europe refused to give a favorable review to laquinimod, a potential successor treatment to Teva's multiple sclerosis drug Copaxone, which faces generic competition in May.
Teva and its multiple sclerosis partner Active Biotech rolled out some new top-line Phase III data on their troubled program for the oral multiple sclerosis drug laquinimod--still Teva's best shot at protecting the $4 billion franchise built up for Copaxone.
Don't be too surprised if Teva starts to make fresh headlines on the M&A side of the business. CEO Shlomo Yanai is telling reporters the company is acutely aware of just how badly it needs to
Teva's late-stage oral MS drug laquinimod flunked the second of three Phase III studies, the latest in a series of disappointments. Company officials say they can explain why the treatment failed to
With a multibillion-dollar market at stake, Teva shares were dented yesterday afternoon after word spread that its oral MS drug laquinimod cut relapses at a lower rate than standard injectable
Israel-based Teva Pharmaceutical announced today that the FDA has granted the Fast Track designation to laquinimod, its investigational treatment for relapsing-remitting multiple sclerosis (RRMS).